Jonathan Gardner

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in supply.

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Biosimilar competition is expected in early January for the company's second highest-selling drug, putting greater focus on newer products' market trajectory.

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The antibody drug conjugate didn't help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

November 1, 2008 | Dermatology Author and Disclosure Information

In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.